| Name | Title | Contact Details |
|---|
At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to her, today and every day.
The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...
Quantum Immunologics is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Indiva is a Canadian licensed producer of premium cannabis and cannabis products, and a provider of extraction, manufacturing and refinement services.
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.